Humana First to Cover TMS Therapy for Adolescents

May 15, 2024 -- Neuronetics, Inc. (NASDAQ: STIM), a leader in medical technology for neurohealth disorders, has announced that Humana is the first commercial insurer to update its policy following recent FDA clearance for the use of NeuroStar TMS (transcranial magnetic stimulation) as an adjunctive treatment for major depressive disorder (MDD) in adolescents aged 15-21. This policy adjustment impacts approximately 600,000 individuals under Humana’s commercial coverage in the United States. Previously, Humana’s TMS coverage was limited to individuals 18 years and older. Now, the policy includes provisions for adolescents aged 15-17, subject to review by a medical director. This update became effective on April 25, 2024, just a month after the FDA cleared NeuroStar TMS for this younger age group on March 25, 2024.

Keith J. Sullivan, President & CEO of Neuronetics, highlighted the importance of this development, saying, “The FDA clearance for NeuroStar TMS is the most significant treatment advancement in years for the often-underserved adolescent patient population. Humana’s quick action to acknowledge NeuroStar’s availability for young people 15 and older underscores this urgent mental health need.” Sullivan also noted that the company's health policy strategy is driving positive policy changes for TMS coverage, benefiting not only adolescents with depression but also their families.

Neuronetics is uniquely positioned to advocate for such changes, being the only TMS company with this specific FDA clearance and having a dedicated health policy team that collaborates with providers and insurers to push for updated health policies.

Adolescent depression is a complex condition affecting an estimated 4.3 million U.S. adolescents aged 15-21. This mental health disorder can disrupt critical aspects of development, including academic performance, peer relationships, and overall emotional well-being. NeuroStar Advanced Therapy is now indicated as an adjunct for treating MDD in this age group.

Neuronetics is dedicated to mental health, emphasizing its importance on par with physical health. As a global leader in neuroscience, the company aims to redefine both patient and physician expectations with its NeuroStar Advanced Therapy for Mental Health. NeuroStar offers a non-drug, noninvasive treatment option that can significantly improve the quality of life for individuals suffering from neurohealth conditions when traditional medications have not been effective. NeuroStar is indicated for treating depressive episodes and reducing anxiety symptoms in adult patients with MDD who have not achieved satisfactory improvement with previous antidepressant treatments. It is also FDA-cleared for treating obsessive-compulsive disorder in adults and as an adjunct for MDD in adolescents aged 15-21. With over 6.4 million treatments delivered, NeuroStar Advanced Therapy is the leading TMS treatment for MDD in adults. Neuronetics remains committed to transforming lives through exceptional treatment options that yield extraordinary results.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!